Malignant Epithelial Tumor of Ovary disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MLG164 MIFTS: 26	Malignant Epithelial Tumor of Ovary Categories: Cancer diseases, Rare diseases, Reproductive diseases
Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Malignant Epithelial Tumor of Ovary

MalaCards integrated aliases for Malignant Epithelial Tumor of Ovary:

Name: Malignant Epithelial Tumor of Ovary ⁵⁸

Ovarian Malignant Epithelial Tumor ⁵⁸

Epithelial Cancer of Ovary ⁵⁸

Ovarian Epithelial Cancer ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁸

Rare gynaecological and obstetric diseases

External Ids:

UMLS via Orphanet ⁷² C0677886

Orphanet ⁵⁸ ORPHA398934

Sources

Summaries for Malignant Epithelial Tumor of Ovary

MalaCards based summary : Malignant Epithelial Tumor of Ovary, also known as ovarian malignant epithelial tumor, is related to ovarian epithelial cancer and malignant non-epithelial tumor of ovary. The drugs Docetaxel and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and bone.

Sources

Related Diseases for Malignant Epithelial Tumor of Ovary

Diseases related to Malignant Epithelial Tumor of Ovary via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 21)

#	Related Disease	Score
1	ovarian epithelial cancer	12.6
2	malignant non-epithelial tumor of ovary	11.5
3	ovary transitional cell carcinoma	11.3
4	ovarian cancer	10.5
5	serous cystadenocarcinoma	10.1
6	cystadenoma	10.0
7	ovarian cyst	10.0
8	ovarian serous cystadenocarcinoma	10.0
9	prostate cancer	9.8
10	polycystic kidney disease 4 with or without polycystic liver disease	9.8
11	ovarian cancer 1	9.8
12	endometrial cancer	9.8
13	neutropenia	9.8
14	papillary serous adenocarcinoma	9.8
15	transitional cell carcinoma	9.8
16	endometriosis	9.8
17	adenocarcinoma	9.8
18	cystadenocarcinoma	9.8
19	ovary adenocarcinoma	9.8
20	peritonitis	9.8
21	appendicitis	9.8

Graphical network of the top 20 diseases related to Malignant Epithelial Tumor of Ovary:

Sources

Symptoms & Phenotypes for Malignant Epithelial Tumor of Ovary

Sources

Drugs & Therapeutics for Malignant Epithelial Tumor of Ovary

Drugs for Malignant Epithelial Tumor of Ovary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 292)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Topotecan

Approved, Investigational

Phase 3

123948-87-8, 119413-54-6

60700

Gemcitabine

Approved

Phase 3

95058-81-4

60750

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Melphalan

Approved

Phase 3

148-82-3

460612 4053

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

Tamoxifen

Approved

Phase 3

10540-29-1

2733526

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Ondansetron

Approved

Phase 3

99614-02-5

4595

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

5743

Epirubicin

Approved

Phase 3

56420-45-2

41867

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Itraconazole

Approved, Investigational

Phase 3

84625-61-6

55283

Captopril

Approved

Phase 3

62571-86-2

44093

Fluconazole

Approved, Investigational

Phase 3

86386-73-4

3365

Ribavirin

Approved

Phase 3

36791-04-5

37542

Palivizumab

Approved, Investigational

Phase 3

188039-54-5

Acyclovir

Approved

Phase 3

59277-89-3

2022

Caspofungin

Approved

Phase 3

162808-62-0, 179463-17-3

2826718 468682

Amphotericin B

Approved, Investigational

Phase 3

1397-89-3

5280965 14956

Cisplatin

Approved

Phase 3

15663-27-1

2767 441203 84093

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

Carboplatin

Approved

Phase 2, Phase 3

41575-94-4

10339178 38904 498142

Mitoxantrone

Approved, Investigational

Phase 3

65271-80-9

4212

Estradiol

Approved, Investigational, Vet_approved

Phase 3

50-28-2

5757

Norgestimate

Approved, Investigational

Phase 3

35189-28-7

6540478

Moxifloxacin

Approved, Investigational

Phase 3

354812-41-2, 151096-09-2

152946

Ethinyl Estradiol

Approved

Phase 3

57-63-6

5991

Polyestradiol phosphate

Approved

Phase 3

28014-46-2

Mycophenolic acid

Approved

Phase 3

24280-93-1

446541

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Dehydroepiandrosterone

Approved, Investigational, Nutraceutical

Phase 3

53-43-0

9860744

Pyridoxine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 3

65-23-6

1054

Pancreatic Polypeptide

Investigational

Phase 3

59763-91-6

Anti-Infective Agents

Phase 3

Anti-Bacterial Agents

Phase 3

Liver Extracts

Phase 3

topoisomerase I inhibitors

Phase 3

Antiviral Agents

Phase 3

Antimetabolites

Phase 3

Cola

Phase 3

Gastrointestinal Agents

Phase 3

Liposomal doxorubicin

Phase 3

31703

Citrate

Phase 3

Estrogen Antagonists

Phase 3

Estrogen Receptor Antagonists

Phase 3

Anesthetics

Phase 3

Interventional clinical trials:

(show top 50) (show all 424)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer	Unknown status	NCT00002477	Phase 3	carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
2	Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II)	Unknown status	NCT01087268	Phase 3
3	Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium	Unknown status	NCT00004115	Phase 3
4	A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY	Unknown status	NCT00045461	Phase 2, Phase 3	carboplatin;ifosfamide
5	Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy	Completed	NCT00382811	Phase 3	phenoxodiol;carboplatin;placebo
6	Amifostine as a Toxicity Protectant in Ovarian Cancer in Chemotherapy Treated Patients: A Pilot Phase III Randomized Controlled Trial	Completed	NCT00004166	Phase 3	amifostine trihydrate
7	ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer	Completed	NCT00483782	Phase 3	carboplatin;paclitaxel
8	Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan	Completed	NCT00006454	Phase 3	carboplatin;paclitaxel;topotecan hydrochloride
9	A Randomized Phase III Trial of Sequential High Dose Chemotherapy or Standard Chemotherapy for Optimally Debulked FIGO Stage III and IV Ovarian Cancer	Completed	NCT00004921	Phase 3	carboplatin;cyclophosphamide;melphalan;paclitaxel
10	A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer	Completed	NCT00003998	Phase 3	carboplatin;docetaxel;paclitaxel
11	Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]	Completed	NCT00102973	Phase 3	TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
12	SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers	Completed	NCT00098878	Phase 3	carboplatin
13	A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma	Completed	NCT00075712	Phase 2, Phase 3	carboplatin;paclitaxel
14	A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV	Completed	NCT00052468	Phase 3	TCG;TC
15	A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Completed	NCT00263822	Phase 3	erlotinib hydrochloride
16	A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis	Completed	NCT00016380	Phase 3	dexamethasone;ondansetron
17	A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy	Completed	NCT00006453	Phase 3	carboplatin;gemcitabine hydrochloride
18	A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma	Completed	NCT00003644	Phase 3	carboplatin;paclitaxel
19	Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy	Completed	NCT00003120	Phase 3	paclitaxel
20	A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma	Completed	NCT00002717	Phase 3	cisplatin;paclitaxel
21	A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy	Completed	NCT00043082	Phase 3	carboplatin;pegylated liposomal doxorubicin hydrochloride
22	A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer	Completed	NCT00028743	Phase 3	carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
23	A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery	Completed	NCT00003695	Phase 3	chemotherapy
24	Randomized Trial on Chemosensitivity Testing in Advanced Primary Ovarian Carcinoma (Phase III)	Completed	NCT00003214	Phase 3	carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
25	A RANDOMISED TRIAL OF PACLITAXEL (TAXOL) IN COMBINATION WITH PLATINUM CHEMOTHERAPY VS. CONVENTIONAL PLATINUM-BASED CHEMOTHERAPY IN THE TREATMENT OF WOMEN WITH RELAPSED OVARIAN CANCER	Completed	NCT00002894	Phase 3	carboplatin;cisplatin;paclitaxel
26	A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA	Completed	NCT00002568	Phase 3	cisplatin;paclitaxel
27	A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer	Completed	NCT00004934	Phase 3	carboplatin;epirubicin hydrochloride;paclitaxel
28	A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy	Completed	NCT00041080	Phase 3	tamoxifen citrate;thalidomide
29	A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma	Completed	NCT00003636	Phase 3	carboplatin;cisplatin
30	Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation	Completed	NCT00004230	Phase 3	captopril;cyclophosphamide
31	A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients	Completed	NCT00003883	Phase 3	fluconazole;itraconazole
32	A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT)	Completed	NCT00014391	Phase 3	ribavirin
33	A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants	Completed	NCT00045292	Phase 3	acyclovir;acyclovir sodium;valacyclovir
34	Music Video and Adolescent/Young Adult Resilience During Transplant	Completed	NCT00305851	Phase 3
35	A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma	Completed	NCT00003322	Phase 3	cisplatin;paclitaxel
36	A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials	Completed	NCT00003938	Phase 3	liposomal amphotericin B
37	A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia	Completed	NCT00008359	Phase 3	caspofungin acetate;liposomal amphotericin B
38	A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone Vs. Delayed Treatment Based On Conventional Clinical Indicators	Completed	NCT00002895	Phase 3	chemotherapy
39	Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial	Completed	NCT01376349	Phase 3	prasterone
40	A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma	Completed	NCT00011986	Phase 3	Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
41	A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome)	Completed	NCT00245050	Phase 3	Placebo;doxorubicin HCL liposome
42	A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
43	Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial	Recruiting	NCT01611766	Phase 3	Salvage Chemotherapy
44	A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	Active, not recruiting	NCT00951496	Phase 3	Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
45	GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262	Active, not recruiting	NCT01167712	Phase 3	Carboplatin;Paclitaxel
46	Assessment of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer	Not yet recruiting	NCT03220932	Phase 3	Chemotherapy and bevacizumab (CT-BEV)
47	A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer	Suspended	NCT01376752	Phase 3	HIPEC
48	A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer	Suspended	NCT01170650	Phase 3	EC145;Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®);placebo;EC20
49	A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY	Terminated	NCT00002819	Phase 3	carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
50	Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)	Terminated	NCT00350948	Phase 3	Telcyta;Liposomal Doxorubicin

Search NIH Clinical Center for Malignant Epithelial Tumor of Ovary

Sources

Genetic Tests for Malignant Epithelial Tumor of Ovary

Sources

Anatomical Context for Malignant Epithelial Tumor of Ovary

MalaCards organs/tissues related to Malignant Epithelial Tumor of Ovary:

⁴⁰

Ovary, T Cells, Bone, Bone Marrow, Breast, Lung, Testes

Sources

Publications for Malignant Epithelial Tumor of Ovary

Articles related to Malignant Epithelial Tumor of Ovary:

(show top 50) (show all 307)

#	Title	Authors	PMID	Year
1	Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors. ⁶¹	Chin CD...Rao J	32404957	2020
2	Does Saving Uterus Save Ovaries? ⁶¹	Khadilkar S	32255946	2020
3	Differentiation of borderline tumors from type I ovarian epithelial cancers on CT and MR imaging. ⁶¹	Yang S...Tang G	32162020	2020
4	HSPA1A, HSPA1L and TRAP1 heat shock genes may be associated with prognosis in ovarian epithelial cancer. ⁶¹	De Andrade WP...Da Silva Filho AL	31897148	2020
5	Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway. ⁶¹	Gao Y...Guo H	32231719	2020
6	Ovarian Cancer Incidence in the Multi-Ethnic Asian City-State of Singapore 1968-2012. ⁶¹	Hwang JY...Chay WY	31870095	2019
7	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. ⁶¹	Sakellariou-Thompson D...Bernatchez C	31602489	2019
8	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. ⁶¹	Coleridge SL...Morrison J	31684686	2019
9	Differential Expression Pattern of Epithelial Mesenchymal Transition Gens: AXL, GAS6, Claudin-1, and Cofilin-1, in Different Stages of Epithelial Ovarian Cancer. ⁶¹	Hassani E...Mansoori Derakhshan S	31700829	2019
10	Genistein upregulates cyclin D1 and CDK4 expression and promotes the proliferation of ovarian cancer OVCAR-5 cells. ⁶¹	Wang Y...Pan S	31465770	2019
11	Expression levels of MRP1, GST-π, and GSK3β in ovarian cancer and the relationship with drug resistance and prognosis of patients. ⁶¹	Tong X...Wang X	31289467	2019
12	Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer. ⁶¹	Kim SY...Kwon BS	31316041	2019
13	Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. ⁶¹	Zhang H...Zhang G	30963272	2019
14	Magnetic resonance imaging in categorization of ovarian epithelial cancer and survival analysis with focus on apparent diffusion coefficient value: correlation with Ki-67 expression and serum cancer antigen-125 level. ⁶¹	Zhang G...Zhang H	31242916	2019
15	PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. ⁶¹	Kim KH...Hwang C	31208449	2019
16	Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. ⁶¹	Mari R...Sabatier R	31167492	2019
17	Mining Featured Biomarkers Linked with Epithelial Ovarian CancerBased on Bioinformatics. ⁶¹	Alur VC...Vastrad C	30970615	2019
18	[Surgery in early-stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. ⁶¹	Bolze PA...Bourgin C	30686727	2019
19	The effects of ovarian cancer cell-derived exosomes on vascular endothelial growth factor expression in endothelial cells. ⁶¹	Ghorbanian M...Ataei F	31645849	2019
20	Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma. ⁶¹	Chang B...Yang G	30428884	2018
21	Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. ⁶¹	Zhang L...Zhou Q	30059681	2018
22	Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. ⁶¹	Oza A...Banerjee S	29454514	2018
23	Activation of hedgehog signaling and its association with cisplatin resistance in ovarian epithelial tumors. ⁶¹	Song X...Guo H	29552194	2018
24	Identification of Genes and Pathways Involved in Ovarian Epithelial Cancer by Bioinformatics Analysis. ⁶¹	Zhou Y...Hong L	30210623	2018
25	Splenectomy during cytoreductive surgery in epithelial ovarian cancer. ⁶¹	Sun H...Shen K	30254490	2018
26	Stably Fluorescent Cell Line of Human Ovarian Epithelial Cancer Cells SK-OV-3ip-red. ⁶¹	Konovalova EV...Deev SM	29124539	2017
27	Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene. ⁶¹	Griscelli F...Bennaceur Griscelli A	29034880	2017
28	The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer. ⁶¹	Fan HY...Liu YF	29028099	2017
29	(E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol suppresses ovarian cancer cell growth via inhibition of ERK and STAT3. ⁶¹	Zheng J...Hong JT	28277616	2017
30	Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. ⁶¹	Wang B...Yang GZ	28693156	2017
31	Expression of inflammatory cytokines in ovarian epithelial cancer and their correlation. ⁶¹	Tang YJ...Yang XS	28685546	2017
32	BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions. ⁶¹	Wang Y...Zheng W	28270171	2017
33	[HORMONE REPLACEMENT THERAPY AFTER GYNECOLOGICAL MALIGNANCIES]. ⁶¹	Michaan N...Grisaru D	28551932	2017
34	[MicroRNA Analysis in Epithelial Ovarian Cancer]. ⁶¹	Sommerova L...Hrstka R	28471201	2017
35	Epithelial Ovarian Cancer Diagnosis of Second-Harmonic Generation Images: A Semiautomatic Collagen Fibers Quantification Protocol. ⁶¹	Zeitoune AA...Adur J	28469386	2017
36	The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. ⁶¹	Zhuang R...Liu T	28796802	2017
37	Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer. ⁶¹	Liu NF...Yu H	29953793	2017
38	The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. ⁶¹	Foster JM...Esquivel J	27792292	2016
39	Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus. ⁶¹	Malecki M...Tombokan X	27905089	2016
40	Platelets are not hyperreactive in patients with ovarian cancer. ⁶¹	Feng S...Afshar-Kharghan V	27185008	2016
41	Regulation of exosomes released from normal ovarian epithelial cells and ovarian cancer cells. ⁶¹	Zhang W...Peng P	27714673	2016
42	Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma. ⁶¹	Hua Y...Ng SW	27602775	2016
43	New halogenated constituents from Mangifera zeylanica Hook.f. and their potential anti-cancer effects in breast and ovarian cancer cells. ⁶¹	Ediriweera MK...de Silva ED	27224244	2016
44	Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma. ⁶¹	de Cristofaro T...Zannini M	27259239	2016
45	Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. ⁶¹	Ghezzi F...Scambia G	27017986	2016
46	Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer. ⁶¹	Liu Z...Chen T	27445438	2016
47	Tumor suppressor in lung cancer 1 gene expression in epithelial ovarian cancer. ⁶¹	Qu H...Yang A	27146728	2016
48	Nedd4L expression is decreased in ovarian epithelial cancer tissues compared to ovarian non-cancer tissue. ⁶¹	Yang Q...Han X	26554540	2015
49	Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition. ⁶¹	Zhang J...Qi C	26323892	2015
50	Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells. ⁶¹	Zhong ZF...Wang YT	26553648	2015

Sources

Genes for Malignant Epithelial Tumor of Ovary

Sources

Variations for Malignant Epithelial Tumor of Ovary

Sources

Expression for Malignant Epithelial Tumor of Ovary

Search GEO for disease gene expression data for Malignant Epithelial Tumor of Ovary.

Sources

Pathways for Malignant Epithelial Tumor of Ovary

Sources

GO Terms for Malignant Epithelial Tumor of Ovary

Sources

Sources for Malignant Epithelial Tumor of Ovary

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia